Alterations of von Willebrand factor and ristocetin cofactor activity during atrial fibrillation

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 1, 2009, Pages 103-108

  Kalyoncu, Umut ^a   Dizdar, Omer ^a   Erkan Duman, Ali ^a   Karadag, Omer ^a   Tufan, Abdurrahman ^a   Yucel, Orhan ^a   Tayfur, Oyku ^a   Sen, Didem ^a   Ulger, Zekeriya ^a   Kepez, Alper ^a   Kocabas, Ugur ^a   Haznedaroglu, Ibrahim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Atrial fibrillation; Mitral stenosis; Ristocetin cofactor activity; Von Willebrand factor

Indexed keywords

ANTIGEN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MALE; MITRAL VALVE STENOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; RISTOCETIN COFACTOR ASSAY; SINUS RHYTHM; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COMORBIDITY; DIABETIC ANGIOPATHIES; ENDOTHELIUM; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MITRAL VALVE STENOSIS; RISTOCETIN; VON WILLEBRAND FACTOR;

EID: 58449115744     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607305115     Document Type: Article

References (31)

1. Lip GY, Blann A. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders ? Cardiovasc Res. 1997 ; 34: 255-265.
2. Roldan V., Marin F., Garcia-Herola A., et al. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res. 2005 ; 116: 321-325.
3. Jager A., van Hinsbergh VW, Kostense PJ, et al. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999 ; 19: 3071-3078.
4. van Mourik JA, Boertjes R., Huisveld IA, et al. Von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood. 1999 ; 94: 179-185.
5. Vischer UM, Emeis JJ, Bilo HJ, et al. Von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII). Thromb Haemost. 1998 ; 80: 1002-1007.
6. Fukuchi M., Watanabe J., Kumagai K., et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol. 2001 ; 37: 1436-1442.
7. Ileri M., Buyukasik Y., Ileri NS, et al. Activation of blood coagulation in patients with mitral stenosis and sinus rhythm. Am J Cardiol. 1998 ; 81: 795-797.
8. Li-Saw-Hee FL, Blann AD, Gurney D., et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 2001 ; 22: 1741-1747.
9. Conway DS, Pearce LA, Chin BS, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002 ; 106: 1962-1967.
10. Hatzinikolaou-Kotsakou E., Kartasis Z., Tziakas D., et al. Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations ? J Thromb Thrombolysis. 2003 ; 16: 155-161.
11. Budde U., Drewke E., Mainusch K., et al. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost. 2002 ; 28: 173-190.
12. Blackshear JL, Pearce LA, Hart RG, et al. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke. 1999 ; 30: 834-840.
13. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med. 1998 ; 128: 639-647.
14. Li-Saw-Hee FL, Blann AD, Lip GY Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000 ; 31: 828-833.
15. Atalar E., Ozmen F., Haznedaroglu I., et al. Impaired fibrinolytic capacity in rheumatic mitral stenosis with or without atrial fibrillation and nonrheumatic atrial fibrillation. Int J Hematol. 2002 ; 76: 192-195.
16. Atalar E., Haznedaroglu IC, Acil T., et al. Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia. Platelets. 2003 ; 14: 407-411.
17. Boyaci A., Topaloglu S., Yilmaz S., et al. Regional left atrial coagulation and fibrinolytic activities in patients with mitral stenosis. Jpn Heart J. 2004 ; 45: 779-788.
18. Kumagai K., Fukuchi M., Ohta J., et al. Expression of the von Willebrand factor in atrial endocardium is increased in atrial fibrillation depending on the extent of structural remodeling. Circ J. 2004 ; 68: 321-327.
19. Penny WF, Weinstein M., Salzman EW, et al. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation. 1991 ; 83: 1630-1636.
20. Altinbas A., Dogan A., Ozguner F., et al. Activity of factor VIIa and von Willebrand factor in non-insulin-dependent diabetic subjects with coronary artery disease. J Int Med Res. 1999 ; 27: 185-190.
21. Li-Saw-Hee FL, Blann AD, Edmunds E., et al. Effect of acute exercise on the raised plasma fibrinogen, soluble P-selectin and von Willebrand factor levels in chronic atrial fibrillation. Clin Cardiol. 2001 ; 24: 409-414.
22. Lip GY, Lowe GD, Rumley A., et al. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995 ; 73: 527-533.
23. Lip GY, Pearce LA, Chin BS, et al. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart. 2005 ; 91: 759-763.
24. Goldsmith IR, Foo LS, Blann AD, et al. Increased platelet activation and endothelial dysfunction in patients with atrial fibrillation immediately following percutaneous balloon mitral valvuloplasty. Clin Cardiol. 2000 ; 23: 587-590.
25. Conway DS, Heeringa J., Van Der Kuip DA, et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke. 2003 ; 34: 413-417.
26. Ouvina SM, La Greca RD, Zanaro NL, et al. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res. 2001 ; 102: 107-114.
27. Ibrahim HA, El-Meligi AA, Abdel-Hamid M., et al. Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus. Med Sci Monit. 2004 ; 10: CR85 - CR89.
28. Lowe GD Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb. 2003 ; 33: 455-457.
29. Verrotti A., Greco R., Basciani F., et al. Von Willebrand factor and its propeptide in children with diabetes. Relation between endothelial dysfunction and microalbuminuria. Pediatr Res. 2003 ; 53: 382-386.
30. Aso Y., Fujiwara Y., Tayama K., et al. Elevation of von Willebrand factor in plasma in diabetic patients with neuropathic foot ulceration. Diabet Med. 2002 ; 19: 19-26.
31. Pomilio M., Mohn A., Verrotti A., et al. Endothelial dysfunction in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002 ; 15: 343-361.